NCT04384666View on ClinicalTrials.gov

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

August 5, 2020

Study Completion Date

August 10, 2020

Conditions
Parkinson Disease
Interventions
DRUG

LY03003 (rotigotine extended release microspheres for intramuscular [IM] injection)

LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)

OTHER

Neupro 4 mg / 24 Hr. Transdermal Patch

Neupro 4 mg /24 Hr. Transdermal Patch

Trial Locations (1)

84124

Pharmaceutical Research Associates, Inc., Salt Lake City

All Listed Sponsors
lead

Luye Pharma Group Ltd.

INDUSTRY

NCT04384666 - A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | Biotech Hunter | Biotech Hunter